Literature DB >> 20735409

Are there functional β₃-adrenoceptors in the human heart?

Martin C Michel1, Sian E Harding, Richard A Bond.   

Abstract

β₃-Adrenoceptor mRNA is expressed in the human heart, but corresponding receptor protein has not yet consistently been demonstrated. Furthermore, their physiological role remains highly controversial. For example, in human atria these receptors apparently do not promote cAMP formation. Evidence presented in this issue of the BJP suggests that a previously reported β₃-adrenoceptor-mediated stimulation of Ca(2+) channels at room temperature is absent at physiological temperatures, and that β₃-adrenoceptors have no effect on atrial contraction. Drugs classified as β₃-adrenoceptor agonists cause contraction in human atria but in most cases this involves β₁- and/or β₂-adrenoceptors. In contrast, in human ventricles β₃-adrenoceptor agonists can exhibit negative inotropic effects, potentially involving Pertussis toxin-sensitive G-proteins and activation of a NO synthase. However, firmer pharmacological evidence is required that these effects indeed occur via β₃-adrenoceptors. Whether the expected future use of β₃-adrenoceptor agonists in the treatment of urinary bladder dysfunction is associated with adverse events related to cardiac function remains to be determined from clinical studies.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20735409      PMCID: PMC3042193          DOI: 10.1111/j.1476-5381.2010.01005.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  41 in total

1.  The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.

Authors:  Jillian G Baker
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

Review 2.  Modulation of human cardiac function through 4 beta-adrenoceptor populations.

Authors:  A J Kaumann; P Molenaar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1997-06       Impact factor: 3.000

Review 3.  Tools to study beta3-adrenoceptors.

Authors:  Wim Vrydag; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-01-09       Impact factor: 3.000

Review 4.  Beta 3 and atypical beta-adrenoceptors.

Authors:  J R Arch; A J Kaumann
Journal:  Med Res Rev       Date:  1993-11       Impact factor: 12.944

5.  Functional beta3-adrenoceptor in the human heart.

Authors:  C Gauthier; G Tavernier; F Charpentier; D Langin; H Le Marec
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

6.  Interspecies differences in the cardiac negative inotropic effects of beta(3)-adrenoceptor agonists.

Authors:  C Gauthier; G Tavernier; J N Trochu; V Leblais; K Laurent; D Langin; D Escande; H Le Marec
Journal:  J Pharmacol Exp Ther       Date:  1999-08       Impact factor: 4.030

7.  Potent and selective human beta(3)-adrenergic receptor antagonists.

Authors:  M R Candelore; L Deng; L Tota; X M Guan; A Amend; Y Liu; R Newbold; M A Cascieri; A E Weber
Journal:  J Pharmacol Exp Ther       Date:  1999-08       Impact factor: 4.030

Review 8.  beta3-adrenoceptors in the cardiovascular system: putative roles in human pathologies.

Authors:  Bertrand Rozec; Chantal Gauthier
Journal:  Pharmacol Ther       Date:  2006-02-15       Impact factor: 12.310

9.  The contribution of classical (beta1/2-) and atypical beta-adrenoceptors to the stimulation of human white adipocyte lipolysis and right atrial appendage contraction by novel beta3-adrenoceptor agonists of differing selectivities.

Authors:  M V Sennitt; A J Kaumann; P Molenaar; L J Beeley; P W Young; J Kelly; H Chapman; S M Henson; J M Berge; D K Dean; N R Kotecha; H K Morgan; H K Rami; R W Ward; M Thompson; S Wilson; S A Smith; M A Cawthorne; M J Stock; J R Arch
Journal:  J Pharmacol Exp Ther       Date:  1998-06       Impact factor: 4.030

10.  Mechanisms of beta 3-adrenoceptor-induced eNOS activation in right atrial and left ventricular human myocardium.

Authors:  Klara Brixius; Wilhelm Bloch; Christian Pott; Andreas Napp; Andreas Krahwinkel; Christoph Ziskoven; Marco Koriller; Uwe Mehlhorn; J Hescheler; Bernd Fleischmann; Robert H G Schwinger
Journal:  Br J Pharmacol       Date:  2004-10-04       Impact factor: 8.739

View more
  12 in total

Review 1.  Cardiac β3 -adrenoceptors-A role in human pathophysiology?

Authors:  Ebru Arioglu-Inan; Gizem Kayki-Mutlu; Martin C Michel
Journal:  Br J Pharmacol       Date:  2019-04-22       Impact factor: 8.739

Review 2.  β3 -Adrenoceptors in the normal and diseased urinary bladder-What are the open questions?

Authors:  Yasuhiko Igawa; Naoki Aizawa; Martin C Michel
Journal:  Br J Pharmacol       Date:  2019-05-03       Impact factor: 8.739

3.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 4.  Mirabegron: potential off target effects and uses beyond the bladder.

Authors:  Nodi Dehvari; Edilson Dantas da Silva Junior; Tore Bengtsson; Dana Sabine Hutchinson
Journal:  Br J Pharmacol       Date:  2018-01-18       Impact factor: 8.739

5.  Physiological Mitochondrial Fragmentation Is a Normal Cardiac Adaptation to Increased Energy Demand.

Authors:  Michael Coronado; Giovanni Fajardo; Kim Nguyen; Mingming Zhao; Kristina Kooiker; Gwanghyun Jung; Dong-Qing Hu; Sushma Reddy; Erik Sandoval; Aleksandr Stotland; Roberta A Gottlieb; Daniel Bernstein
Journal:  Circ Res       Date:  2017-12-12       Impact factor: 17.367

6.  Adrenoceptor sub-type involvement in Ca2+ current stimulation by noradrenaline in human and rabbit atrial myocytes.

Authors:  Priyanka Saxena; Rachel C Myles; Godfrey L Smith; Antony J Workman
Journal:  Pflugers Arch       Date:  2022-09-22       Impact factor: 4.458

7.  Adrenergic pathway activation enhances brown adipose tissue metabolism: a [¹⁸F]FDG PET/CT study in mice.

Authors:  M Reza Mirbolooki; Sanjeev Kumar Upadhyay; Cristian C Constantinescu; Min-Liang Pan; Jogeshwar Mukherjee
Journal:  Nucl Med Biol       Date:  2013-10-01       Impact factor: 2.408

8.  Agonist-induced desensitization of human β3-adrenoceptors expressed in human embryonic kidney cells.

Authors:  Martina B Michel-Reher; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-06-12       Impact factor: 3.000

9.  β3-adrenoceptor impacts apoptosis in cultured cardiomyocytes via activation of PI3K/Akt and p38MAPK.

Authors:  Miao-Miao Ma; Xiao-Li Zhu; Li Wang; Xiao-Fang Hu; Zhong Wang; Jin Zhao; Yi-Tong Ma; Yi-Ning Yang; Bang-Dang Chen; Fen Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-02-03

Review 10.  Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling.

Authors:  Jillian G Baker; Stephen J Hill; Roger J Summers
Journal:  Trends Pharmacol Sci       Date:  2011-03-21       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.